Strides Pharma Science Ltd posts consolidated PAT of Rs. 46.08 crore in Q4FY21

Strides Pharma Science Ltd has reported financial results for the period ended March 31, 2021.

Financial Results (Q4 FY20-21) - QoQ Comparison

The company has reported total income of Rs.921.54 crores during the period ended March 31, 2021 as compared to Rs.845.22 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.46.08 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.37.84 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.5.14 for the period ended March 31, 2021 as compared to Rs.4.22 for the period ended December 31, 2020.

Financials	Q4 FY20-21	Q3 FY20-21	% Change
Total Income	₹ 921.54 crs	₹ 845.22 crs	9.03%
Net Profit	₹ 46.08 crs	₹ 37.84 crs	21.78%
EPS	₹ 5.14	₹ 4.22	21.8%

Financial Results (Q4 FY20-21) - YoY Comparison

The company has reported total income of Rs.921.54 crores during the period ended March 31, 2021 as compared to Rs.636.29 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.46.08 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.(203.92) crores for the period ended March 31, 2020.

The company has reported EPS of Rs.5.14 for the period ended March 31, 2021 as compared to Rs.(22.76) for the period ended March 31, 2020.

Financials	Q4 FY20-21	Q4 FY19-20	% Change
Total Income	₹ 921.54 crs	₹ 636.29 crs	44.83%
Net Profit	₹ 46.08 crs	₹ (203.92) crs	122.6%
EPS	₹ 5.14	₹ (22.76)	122.58%

Financial Results (Year ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.3367.29 crores during the 12 months period ended March 31, 2021 as compared to Rs.2805.08 crores during the 12 months period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.268.44 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.36.39 crores for the 12 months period ended March 31, 2020.

The company has reported EPS of Rs.29.92 for the 12 months period ended March 31, 2021 as compared to Rs.4.06 for the 12 months period ended March 31, 2020.

Financials	Year Ended FY20-21	Year Ended FY19-20	% Change
Total Income	₹ 3367.29 crs	₹ 2805.08 crs	20.04%
Net Profit	₹ 268.44 crs	₹ 36.39 crs	637.68%
EPS	₹ 29.92	₹4.06	636.95%

Commenting on the performance, Dr R Ananthanarayanan, Managing Director & CEO, remarked, "Amidst a tough operating environment, we are pleased to have delivered a healthy performance across all businesses in FY21. Our regulated markets franchise which now contributes 80% of revenues has seen significant ramp up in FY21 growing 21% YoY inline with our outlook. The emerging markets business witnessed a strong bounce back in FY21 benefitting from launch of TLD albeit at lower gross margins.

Our revenue during the year has grown 29% YoY to ₹33,308m with an EBITDA growth of 67% to ₹6,497m. EBITDA margin for FY21 was at 19.5%, a healthy expansion of 450bps YoY despite a significant cost increase of ₹1,293m from logistics and Failure to Supply largely owing to COVID-19 related disruptions.

While in the near term we are witnessing operational challenges owing to a rampant second wave of COVID19 in India, we believe we have all the strategic pivots in place to continue on our growth momentum and deliver strong financial outcomes for our stakeholders over the next 3 years."

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.816.6 as compared to the previous close of Rs. 798.2. The total number of shares traded during the day was 101452 in over 2730 trades.

The stock hit an intraday high of Rs. 819.25 and intraday low of 800.15. The net turnover during the day was Rs. 82133153.

Source : Equity Bulls

Keywords